- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07703436
Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
This study will include up to 40 participants with Grade 2 or Grade 3 IDH1-mutant glioma who have undergone surgery and received vorasidenib as their only treatment, experienced radiographic disease progression on vorasidenib (confirmed by Blinded Independent Central Review [BICR] per modified Response Assessment in Neuro-Oncology [RANO] 2.0), and are not in need of immediate chemotherapy or radiotherapy.
연구 개요
상태
정황
개입 / 치료
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Clinical Trials at Nuvation Bio
- 전화번호: 332-208-6102
- 이메일: ClinicalTrials@nuvationbio.com
연구 장소
-
-
California
-
Los Angeles, California, 미국, 90095
- 아직 모집하지 않음
- University of California, Los Angeles
-
수석 연구원:
- Robert Chong, MD
-
연락하다:
- Quan Li
- 전화번호: 310-825-1416
- 이메일: quanli@mednet.ucla.edu
-
San Francisco, California, 미국, 94143
- 아직 모집하지 않음
- University of California, San Francisco
-
수석 연구원:
- John De Groot, MD
-
연락하다:
- Neuro Onc New Patient Coordinator
- 전화번호: 415-353-2193
- 이메일: neurooncnewpatientcoord@ucsf.edu
-
-
Connecticut
-
New Haven, Connecticut, 미국, 06510
- 아직 모집하지 않음
- Yale University
-
수석 연구원:
- Nicholas Blondin, MD
-
연락하다:
- Amy Rodrigues
- 이메일: amy.rodrigues@yale.edu
-
연락하다:
- 이메일: cto-neuro@yale.edu
-
-
Florida
-
Miami, Florida, 미국, 33136
- 아직 모집하지 않음
- University of Miami Health
-
연락하다:
- Leonela Wright
- 전화번호: 305-243-0864
- 이메일: lxw612@med.miami.edu
-
수석 연구원:
- Juan Blaquier, MD
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46202
- 모병
- Indiana University
-
수석 연구원:
- Kathryn Nevel, MD
-
연락하다:
- NeuroOncology Clinical Trials
- 전화번호: 3179634823
- 이메일: neuroct@iu.edu
-
-
Louisiana
-
New Orleans, Louisiana, 미국, 70112
- 아직 모집하지 않음
- LSU LCMC Health Cancer Center
-
수석 연구원:
- Yazmin Odia, MD
-
연락하다:
- Yazmin Odia
- 전화번호: (646) 634-9655
- 이메일: yodia@lsuhsc.edu
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02214
- 아직 모집하지 않음
- Massachusetts General Hospital
-
연락하다:
- Vihang Nakhate
- 전화번호: 617-724-8770
- 이메일: vnakhate@mgh.harvard.edu
-
수석 연구원:
- Vihang Nakhate, MD
-
-
New Jersey
-
New Brunswick, New Jersey, 미국, 08901
- 아직 모집하지 않음
- Rutgers Cancer Institute
-
수석 연구원:
- Morana Vojnic, MD
-
연락하다:
- Kasie Diorio
- 전화번호: 732-235-2465
- 이메일: kassie.diorio@rutgers.edu
-
-
New York
-
New York, New York, 미국, 10016
- 모병
- NYU Langone Health
-
연락하다:
- Jose McFaline-Figueroa, MD
- 전화번호: 212-731-6267
- 이메일: Jose.McFalineFigueroa@nyulangone.org
-
New York, New York, 미국, 10032
- 아직 모집하지 않음
- Columbia University Medical Center
-
수석 연구원:
- Andrew Lassman, MD
-
연락하다:
- Research Nurse Navigator
- 전화번호: 212-342-5162
- 이메일: Cancerclinicaltrials@cumc.columbia.edu
-
-
Ohio
-
Cleveland, Ohio, 미국, 44106
- 아직 모집하지 않음
- Cleveland Clinic
-
수석 연구원:
- Mina Lobbous, MD
-
연락하다:
- Marci Ciolfi
- 전화번호: 216-445-3307
- 이메일: ciolfim@ccf.org
-
Columbus, Ohio, 미국, 43210
- 아직 모집하지 않음
- The Ohio State University Comprehensive Cancer Center
-
연락하다:
- Pierre Giglio
- 전화번호: 614-293-4448
- 이메일: Pierre.Giglio@osumc.edu
-
수석 연구원:
- Pierre Giglio, MD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Key Inclusion Criteria:
- Histologically confirmed Grade 2 or 3 IDH-mutant astrocytoma or IDH-mutant and 1p19q co-deleted oligodendroglioma, according to WHO CNS 2021 criteria
- IDH1 mutation (e.g., R132H/C/G/S/L) based on immunohistochemistry (IHC) (R132H only), PCR, or next generation sequencing (NGS).
- Have had at least 1 prior surgery for glioma (biopsy, sub-total resection, or gross total resection).
- Measurable disease per modified RANO 2.0 confirmed by BICR during Screening.
- Previously treated with vorasidenib and experienced radiographic disease progression during treatment and are not in need of immediate chemotherapy or radiotherapy in the opinion of the Investigator. Disease progression must be confirmed by BICR using modified RANO 2.0.
- Adequate hematologic and organ function
- Expected survival of ≥12 months
Key Exclusion Criteria:
- Any prior anticancer therapy other than surgery (biopsy, sub-total, or gross total resection) and vorasidenib for treatment of glioma.
- Discontinued vorasidenib for toxicity or any reason other than radiographic disease progression
- Prior treatment with anti-angiogenic agents such as Avastin (bevacizumab) or investigational agents for glioma.
- Brainstem or spinal cord involvement either as primary location, site of multifocal involvement, or by significant tumor extension.
- Significant functional or neurocognitive deficits, including uncontrolled seizures
- Evidence of leptomeningeal disease.
- Use of therapeutic doses of steroids for signs/symptoms of glioma. Participants taking physiologic doses (defined as equivalent of <1.5 mg of dexamethasone equivalent) for medical conditions not related to glioma will be permitted.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Safusidenib
Safusidenib 250 mg BID |
Safusidenib administered twice daily as a single agent orally on Days 1 to 28 of a 28-day cycle. Participants may continue treatment until disease progression or another reason for discontinuation occurs. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Objective Response Rate (ORR) per modified Response Assessment in Neuro-Oncology (RANO) 2.0 assessed by Blinded Independent Central Review (BICR)
기간: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
ORR defined as the proportion of participants with the confirmed best overall response of Complete Response (CR), Partial Response (PR) or Minor Response (MR) per modified RANO 2.0, assessed by BICR |
From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
ORR per modified RANO 2.0 assessed by Investigator
기간: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
ORR defined as the proportion of participants with the confirmed best overall response of CR, PR or MR per modified RANO 2.0, assessed by the Investigator |
From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
|
Volumetric Tumor Growth Rate (TGR) by BICR
기간: From historical scans through the final scan in the study, approximately 18 months
|
TGR defined as the percentage change in tumor volume by unit of time, assessed by BICR |
From historical scans through the final scan in the study, approximately 18 months
|
|
Duration of Response (DOR) per modified RANO 2.0 assessed by BICR and by Investigator
기간: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
DOR, time from the first documentation of objective response (CR, PR, or MR) to the date of the first occurrence of radiographic disease progression per modified RANO 2.0 assessed by BICR and by the Investigator or death from any cause, whichever occurs earlier. |
From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
|
Time to Next Intervention (TTNI)
기간: From the date of first dose of study drug until the date of the start of another anticancer treatment or date of death, approximately 18 months
|
TTNI, defined as the time from the first dose of study drug to the initiation of first subsequent anticancer therapy or death from any cause, whichever occurs earlier |
From the date of first dose of study drug until the date of the start of another anticancer treatment or date of death, approximately 18 months
|
|
Progression Free Survival (PFS) per modified RANO 2.0 assessed by BICR and by Investigator
기간: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
PFS, defined as the time from the first dose of study drug to the date of the first occurrence of radiographic disease progression per modified RANO 2.0 assessed by BICR and by the Investigator or death from any cause, whichever occurs earlier. |
From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
|
Time to Response (TTR) per modified RANO 2.0 assessed by BICR and by Investigator
기간: From the date of first dose of study drug to the first documentation of objective response (CR, PR, or MR), approximately 18 months
|
TTR, defined as the time from the first dose of study drug to the first documentation of objective response (CR, PR, or MR) per modified RANO 2.0, assessed by BICR and by the Investigator |
From the date of first dose of study drug to the first documentation of objective response (CR, PR, or MR), approximately 18 months
|
|
Overall Survival (OS)
기간: From the date of first dose of study drug until the date of death, approximately 18 months
|
OS, defined as the time from the first dose of study drug to death from any cause. |
From the date of first dose of study drug until the date of death, approximately 18 months
|
|
Safety and tolerability
기간: From the date of first dose of study drug until 30 days after the date of the last dose of study drug, approximately 18 months
|
The safety and tolerability of safusidenib evaluated based on AEs graded by NCI-CTCAE version 5.0, laboratory abnormalities as graded by NCI-CTCAE version 5.0, vital signs, physical examinations, and ECGs |
From the date of first dose of study drug until 30 days after the date of the last dose of study drug, approximately 18 months
|
|
Seizure Activity
기간: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
Evaluate seizure frequencies and severity including type of seizure, seizure-related AEs, and changes in anti-epileptic medications in participants receiving safusidenib |
From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- NUV-218-G209
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .